72025-60-6 Usage
Description
Leukotriene C4 (LTC4) is a potent agonist for the contraction of smooth muscle and is known for its significant immunomodulatory functions. It is the parent cysteinyl leukotriene produced by the LTC4 synthase-catalyzed conjugation of glutathione to LTA4. LTC4 is synthesized by neutrophils, macrophages, mast cells, and through transcellular metabolism in platelets. As a constituent of the slow-reacting substance of anaphylaxis (SRS-A), it exhibits potent smooth muscle-contracting activity. LTC4-induced bronchoconstriction and enhanced vascular permeability play a role in the pathogenesis of asthma and acute allergic hypersensitivity. The concentration of LTC4 required to produce marked contractions of lung parenchymal strips and isolated tracheal rings is about 1 nM. It is defined as a leukotriene containing cysteine in its structure.
Uses
1. Used in Pharmaceutical Applications:
Leukotriene C4 is used as a therapeutic agent for the treatment of asthma and other allergic conditions due to its potent smooth muscle-contracting activity and its role in the pathogenesis of these diseases.
2. Used in Research and Development:
LTC4 is utilized as a research tool to study the mechanisms underlying asthma, allergic reactions, and other immune system-related conditions. It helps researchers understand the role of leukotrienes in these processes and develop new drugs targeting leukotriene pathways.
3. Used in Drug Delivery Systems:
Similar to gallotannin, novel drug delivery systems could be developed to enhance the applications and efficacy of LTC4 against specific conditions. Various organic and metallic nanoparticles could be employed as carriers for LTC4 delivery, aiming to improve its delivery, bioavailability, and therapeutic outcomes.
4. Used in Diagnostic Applications:
LTC4 can be used as a biomarker for the diagnosis of asthma and other allergic conditions, as well as for monitoring the effectiveness of treatments targeting leukotriene pathways.
5. Used in the Study of Inflammation:
Due to its immunomodulatory functions, LTC4 can be used in research to better understand the role of leukotrienes in inflammation and the development of new anti-inflammatory drugs.
Check Digit Verification of cas no
The CAS Registry Mumber 72025-60-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,2,0,2 and 5 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 72025-60:
(7*7)+(6*2)+(5*0)+(4*2)+(3*5)+(2*6)+(1*0)=96
96 % 10 = 6
So 72025-60-6 is a valid CAS Registry Number.
InChI:InChI=1/C30H47N3O9S/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-25(24(34)15-14-17-27(36)37)43-21-23(29(40)32-20-28(38)39)33-26(35)19-18-22(31)30(41)42/h6-7,9-13,16,22-25,34H,2-5,8,14-15,17-21,31H2,1H3,(H,32,40)(H,33,35)(H,36,37)(H,38,39)(H,41,42)/b7-6-,10-9-,12-11+,16-13+/t22?,23?,24-,25+/m0/s1
72025-60-6Relevant articles and documents
Total synthesis of leukotrienes from butadiene
Rodriguez, Ana,Nomen, Miguel,Spur, Bernd W.,Godfroid, Jean-Jacques,Lee, Tak H.
, p. 2991 - 3000 (2007/10/03)
The total synthesis of leukotrienes has been achieved starting from butadiene by a palladium-catalyzed telomerization at room temperature. A Sharpless catalytic asymmetric epoxidation generated the asymmetric centers with >94% ee. Simple transformations of the key intermediate 15 produced the leukotrienes LTA4 methyl ester (4), LTC4 (1), LTD4 (2) and LTE4 (3), as well as (14S, 15S)-LTA4 methyl ester (24) and the novel [2H2]-LTA4 methyl ester (28). The use of the opposite chiral director in the Sharpless catalytic asymmetric epoxidation gave the key intermediate 15a that has been used in the synthesis of the double epimers of the leukotrienes as well as LTB4.
Biomimetic synthesis of leukotriene A
Atrache,Pai,Sok,Sih
, p. 3443 - 3446 (2007/10/02)
-
Stereospecific total synthesis of a 'slow reacting substance' of anaphylaxis, leukotriene C-1
Corey,Clark,Goto,et al.
, p. 1436 - 1439 (2007/10/02)
-
